Regeneron Furnishes Financial and Operating Results
Summary
Regeneron Pharmaceuticals, Inc. announced its third quarter 2025 financial and operating results on October 28, 2025, via a press release (Ex. 99.1). Revenues increased 1% to $3.75 billion, with GAAP EPS of $13.62 and non-GAAP EPS of $11.83, including an unfavorable $0.68 IPR&D charge. * Dupixent® global net sales rose 27% to $4.86 billion. * EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion. * FDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant cutaneous squamous cell carcinoma. * Positive Phase 3 results were reported for trials in generalized myasthenia gravis, fibrodysplasia ossificans progressiva (FOP), and cat and birch allergies.
Why It Matters
The 1% revenue increase to $3.75 billion and GAAP EPS of $13.62 reflect overall financial performance. Key product sales, like Dupixent's 27% growth and the 28% decrease in total EYLEA sales, show mixed product dynamics. The FDA approval of Libtayo and positive Phase 3 trial results also signal pipeline strength and future potential.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how REGN traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View REGN Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000872589
- Filing Date
- Tuesday, October 28, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive